Keyphrases
Chemotherapy
63%
High-dose Chemotherapy
49%
Breast Cancer Patients
45%
Overall Survival
42%
Phase II Trial
33%
Cisplatin
32%
Breast Cancer
31%
Capecitabine
30%
Doxorubicin
28%
Paclitaxel
26%
Advanced Breast Cancer
26%
Cancer Patients
25%
Hepatocellular Carcinoma
25%
Tumor
24%
Patients with Breast Cancer
24%
Placebo
22%
Progression-free Survival
22%
Recurrence Score
22%
Bevacizumab
21%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Systematic Meta-analysis
21%
Metastatic Breast Cancer
20%
Meta-analysis
20%
Cyclophosphamide
19%
Confidence Interval
19%
Hazard Ratio
19%
Early Breast Cancer
19%
Malignancy
17%
Marrow
17%
Chemotherapy-induced
17%
Hormone Receptor-positive
17%
Oncology
16%
Letrozole
16%
Clinical Outcomes
16%
Adverse Events
16%
Vascular Toxicity
15%
Liver
15%
Gemcitabine
14%
Fertility Preservation
14%
Trastuzumab
14%
Dose-dense Chemotherapy
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
14%
Ribociclib
14%
Granulocyte Colony-stimulating Factor (G-CSF)
13%
Hematopoietic Stem Cells
13%
Pancreatic Cancer
13%
Breast Cancer Recurrence
13%
A3 Adenosine Receptor
13%
Allogeneic Bone Marrow Transplantation
12%
Bone Marrow Mononuclear Cells
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Chemotherapy
89%
Malignant Neoplasm
65%
Overall Survival
46%
Neoplasm
43%
Capecitabine
30%
Progression Free Survival
28%
Disease
27%
Placebo
26%
Paclitaxel
25%
Cisplatin
25%
Epidermal Growth Factor Receptor
25%
Metastatic Breast Cancer
24%
Liver Cell Carcinoma
24%
Pancreas Cancer
22%
Bevacizumab
22%
Adverse Event
21%
Doxorubicin
20%
Cyclophosphamide
20%
Recurrent Disease
18%
Hormone Receptor
18%
Namodenoson
17%
High Dose Chemotherapy
16%
Rash
16%
Gamma Urogastrone
14%
Letrozole
14%
Trastuzumab
14%
Clinical Trial
13%
Mouse
13%
Carmustine
11%
Taxane
11%
Epidermal Growth Factor Receptor 2
11%
Letrozole Plus Ribociclib
11%
Prospective Study
10%
Nanocapsule
10%
Gemcitabine
10%
Solid Malignant Neoplasm
10%
Randomized Controlled Trial
10%
Dyspnea
9%
Ovary Insufficiency
9%
Fluorouracil
9%
Infection
9%
Colorectal Cancer
9%
Cetuximab
8%
Protein Tyrosine Kinase Inhibitor
8%
Ovary Cancer
8%
Adenosine A3 Receptor Agonist
8%
Erlotinib
8%
Biological Marker
8%
Olaparib
8%
Medicine and Dentistry
Breast Cancer
99%
Malignant Neoplasm
61%
Overall Survival
40%
Neoplasm
37%
Placebo
29%
High Dose Chemotherapy
29%
Disease
27%
Cancer
24%
Recurrent Disease
23%
Progression Free Survival
23%
Oncology
22%
Doxorubicin
21%
Pancreas Cancer
20%
Hepatocellular Carcinoma
19%
Radiation Therapy
17%
Hormone Receptor
17%
Adverse Event
16%
Health Care Cost
16%
Capecitabine
15%
Infection
15%
Fertility Preservation
14%
Systematic Review
14%
Clinical Trial
13%
Gamma Urogastrone
13%
Epidermal Growth Factor Receptor 2
13%
Letrozole
12%
Hematopoietic Stem Cell
12%
Arm
12%
Olaparib
11%
Gemcitabine
11%
Meta-Analysis
11%
Dose Densification
10%
Pembrolizumab
10%
Letrozole Plus Ribociclib
10%
Advanced Cancer
10%
Symptom
10%
Cisplatin
10%
Ovary Insufficiency
9%
Quality of Life
9%
Programmed Cell Death
9%
Colorectal Cancer
9%
BRCA Mutation
8%
Hazard Ratio
8%
Trastuzumab
8%
Ovarian Reserve
8%
Breast Carcinoma
8%
Oocyte
8%
Blood Flow
8%
Liver Metastasis
8%
Metastatic Breast Cancer
8%